Related Experiment Video

Updated: Jan 5, 2026

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

13.9K

Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in

Takahiro Sawada1, Kenzo Uzu1, Naoko Hashimoto2

  • 1Hyogo Prefectural Himeji Cardiovascular Center, Division of Cardiovascular Medicine.

Journal of Atherosclerosis and Thrombosis
|October 22, 2019
PubMed
Abstract

Insights

Sodium/glucose cotransporter 2 (SGLT2) inhibitors improved metabolic health and endothelial function in diabetic patients with coronary artery disease. Reduced triglycerides were key to improved vascular function, potentially explaining cardiovascular benefits.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Mechanisms of cardiovascular benefits from SGLT2 inhibitors remain unclear.
  • Diabetic patients with coronary artery disease (CAD) are at high risk for cardiovascular events.

Purpose of the Study:

  • To investigate the effects of SGLT2 inhibitors on hemodynamics, glucose metabolism, lipid profile, and endothelial function.
  • To identify predictors of improved endothelial function.

Main Methods:

  • 50 diabetic patients with CAD received empagliflozin 10 mg/d for six months.
  • Evaluated changes in body composition, glucose/lipid metabolism, insulin resistance, and flow-mediated dilation (FMD).
  • Assessed changes in C-reactive protein and brain natriuretic peptide levels.

Main Results:

  • Empagliflozin significantly reduced body weight, fat percentage, HbA1c, glucose, insulin resistance, and triglycerides.
  • Significant improvements were observed in FMD and C-reactive protein levels.
  • Reduced plasma triglyceride levels were the strongest predictor of FMD improvement.

Conclusions:

  • SGLT2 inhibitors enhance metabolic parameters and endothelial function in diabetic CAD patients.
  • Triglyceride reduction is strongly linked to endothelial recovery and may mediate cardiovascular benefits.
  • Empagliflozin offers a promising therapeutic approach for managing cardiovascular risk in this population.
Keywords:
Diabetes mellitusEndothelial functionFlow-mediated dilatationSodium/glucose transporter 2 inhibitorsTriglycerides

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

527
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.6K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
537
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
798
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
550
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
549
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
828
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K